Evidence map›Paper›PMID 35130322›Full record

ArticlePLoS pathogens2022

High-level carbapenem tolerance requires antibiotic-induced outer membrane modifications.

Andrew N Murtha, Misha I Kazi, Richard D Schargel, Trevor Cross, Conrad Fihn, Vincent Cattoir, Erin E Carlson, Joseph M Boll, Tobias Dörr

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
  3. Journal of bacteriology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Carbapenem-ResistantNanomaterials (Basel, Switzerland) · 2024
    Article
  14. Article
  15. Article
  16. DivergentmBio · 2024
    Article
  17. Article
  18. Evaluation of Expanded 2-Aminobenzothiazole Library for Inhibition ofbioRxiv : the preprint server for biology · 2024
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Andrew N MurthaWeill Institute for Cell and Molecular Biology, Cornell University, Ithaca, New York, United States of America.ORCID 0000-0002-6415-8718
Misha I KaziDepartment of Biology, University of Texas Arlington, Arlington, Texas, United States of America.
Richard D SchargelDepartment of Biology, University of Texas Arlington, Arlington, Texas, United States of America.
Trevor CrossWeill Institute for Cell and Molecular Biology, Cornell University, Ithaca, New York, United States of America.
Conrad FihnDepartment of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota, United States of America.
Vincent CattoirDepartment of Clinical Microbiology and National Reference Center for Antimicrobial Resistance (Lab Enterococci), Rennes University Hospital, Rennes, France; Inserm Unit U1230, University of Rennes 1, Rennes, France.
Erin E CarlsonDepartment of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota, United States of America.
Joseph M BollDepartment of Biology, University of Texas Arlington, Arlington, Texas, United States of America.
Tobias DörrWeill Institute for Cell and Molecular Biology, Cornell University, Ithaca, New York, United States of America.ORCID 0000-0003-3283-9161
Cornell University · USThe University of Texas at Arlington · USUniversity of Minnesota · US

Funding

Cell envelope stress responses and the mechanism of antibiotic tolerance in Gram-negative pathogensR01AI143704 · NIAID · CORNELL UNIVERSITY · PI DOERR, TOBIAS · 2019 to 2023
$2.0M
Reinforcing the barrier: Understanding how cell envelope modifications promote intrinsic antimicrobial tolerance and resistance in Acinetobacter baumanniiR35GM143053 · NIGMS · UNIVERSITY OF TEXAS DALLAS · PI BOLL, JOSEPH MICHAEL · 2021 to 2025
$1.9M
Discovery of New Antibacterial Targets: Probes and Inhibitors of Histidine Kinase ProteinsR01GM134538 · NIGMS · UNIVERSITY OF MINNESOTA · PI CARLSON, ERIN ELIZABETH · 2020 to 2023
$1.2M
NIAID NIH HHS R01 AI143704NIGMS NIH HHS R01 GM134538NIGMS NIH HHS R35 GM143053
6 · The paper itself

Abstract

Antibiotic tolerance is an understudied potential contributor to antibiotic treatment failure and the emergence of multidrug-resistant bacteria. The molecular mechanisms governing tolerance remain poorly understood. A prominent type of β-lactam tolerance relies on the formation of cell wall-deficient spheroplasts, which maintain structural integrity via their outer membrane (OM), an asymmetric lipid bilayer consisting of phospholipids on the inner leaflet and a lipid-linked polysaccharide (lipopolysaccharide, LPS) enriched in the outer monolayer on the cell surface. How a membrane structure like LPS, with its reliance on mere electrostatic interactions to maintain stability, is capable of countering internal turgor pressure is unknown. Here, we have uncovered a novel role for the PhoPQ two-component system in tolerance to the β-lactam antibiotic meropenem in Enterobacterales. We found that PhoPQ is induced by meropenem treatment and promotes an increase in 4-amino-4-deoxy-L-aminoarabinose [L-Ara4N] modification of lipid A, the membrane anchor of LPS. L-Ara4N modifications likely enhance structural integrity, and consequently tolerance to meropenem, in several Enterobacterales species. Importantly, mutational inactivation of the negative PhoPQ regulator mgrB (commonly selected for during clinical therapy with the last-resort antibiotic colistin, an antimicrobial peptide [AMP]) results in dramatically enhanced tolerance, suggesting that AMPs can collaterally select for meropenem tolerance via stable overactivation of PhoPQ. Lastly, we identify histidine kinase inhibitors (including an FDA-approved drug) that inhibit PhoPQ-dependent LPS modifications and consequently potentiate meropenem to enhance lysis of tolerant cells. In summary, our results suggest that PhoPQ-mediated LPS modifications play a significant role in stabilizing the OM, promoting survival when the primary integrity maintenance structure, the cell wall, is removed.

Indexed as

Drug ToleranceAnti-Bacterial AgentsAntimicrobial PeptidesBacterial ProteinsCarbapenemsCell MembraneColistinEnterobacter cloacaeGene Expression RegulationHistidine KinaseHumansLipid ALipopolysaccharidesMembrane ProteinsMicrobial Sensitivity TestsAnti-Bacterial AgentsAntimicrobial PeptidesBacterial ProteinsCarbapenemsColistinHistidine KinaseLipid ALipopolysaccharidesMembrane ProteinsPhoP protein, BacteriaPhoQ protein, Bacteria

Identifiers

PMID35130322
PMCPMC8853513
OpenAlexW3210054524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.